Brexpiprazole

Active ingredient: Brexpiprazole

In short: Brexpiprazole tablets are indicated for: Adjunctive treatment of major depressive disorder (MDD) in adults. Treatment of schizophrenia in adults.

Forms & strengthsBrexpiprazole tablets are available in 6 strengths: 0.25 mg tablets are brown colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “6” on other side. …
LabelAjanta Pharma USA Inc.
Label updatedFeb 22, 2023

What is Brexpiprazole used for?

Brexpiprazole tablets are indicated for:

Adjunctive treatment of major depressive disorder (MDD) in adults.

Treatment of schizophrenia in adults.

âš  Boxed warning (FDA's strongest warning)

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Brexpiprazole tablets are not approved for the treatment of patients with dementia-related psychosis .

Suicidal Thoughts and Behaviors

Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger in short-term studies. Monitor closely for clinical worsening and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of brexpiprazole tablets have not been established in pediatric patients with MDD .

Brexpiprazole dosage

The recommended starting dosage for brexpiprazole tablets as adjunctive treatment of MDD in adults is 0.5 mg or 1 mg once daily, taken orally with or without food .

Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient’s clinical response and tolerability. The maximum recommended daily dosage is 3 mg. Periodically reassess to determine the continued need and appropriate dosage for treatment.

Adults

The recommended starting dosage for brexpiprazole tablets for the treatment of schizophrenia in adults is 1 mg once daily on Days 1 to 4, taken orally with or without food . Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient’s clinical response and tolerability. The recommended target brexpiprazole tablets dosage is 2 mg to 4 mg once daily. The maximum recommended daily dosage is 4 mg.

Pediatric use information is approved for Otsuka Pharmaceutical Company, Ltd.’s Rexulti® (brexpiprazole) tablets. However, due to Otsuka Pharmaceutical Company, LTD.’s marketing exclusivity rights, this drug product is not labeled with that information.

For patients with moderate to severe hepatic impairment (Child-Pugh score greater than or equal to 7), the maximum recommended dosage is 2 mg once daily for patients with MDD, and 3 mg once daily for patients with schizophrenia .

For patients with moderate, severe, or end-stage renal impairment (creatinine clearance CrCl less than 60 mL/minute), the maximum recommended dosage is 2 mg once daily for patients with MDD and 3 mg once daily for patients with schizophrenia .

Dosage adjustments are recommended in patients who are known cytochrome P450 (CYP) 2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers . If the coadministered drug is discontinued, adjust the brexpiprazole tablets dosage to its original level. If the coadministered CYP3A4 inducer is discontinued, reduce the brexpiprazole tablets dosage to the original level over 1 to 2 weeks .

*In the clinical trials examining the adjunctive use of brexpiprazole tablets in the treatment of MDD, dosage was not adjusted for strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). Thus, CYP considerations are already factored into general dosing recommendations, and brexpiprazole tablets may be administered without dosage adjustment in patients with MDD.

Factors | Adjusted Brexpiprazole Tablets Dosage

CYP2D6 Poor Metabolizers

CYP2D6 poor metabolizers | Administer half of the usual dose.

Known CYP2D6 poor metabolizers taking strong/moderate CYP3A4 inhibitors | Administer a quarter of the usual dose. …

How to take Brexpiprazole — instructions & advice from the label

Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide).

Suicidal Thoughts and Behaviors

Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down, and instruct them to report such symptoms to the healthcare provider .

Dosage and Administration

Advise patients that brexpiprazole tablets can be taken with or without food. Advise patients regarding importance of following dosage escalation instructions .

Neuroleptic Malignant Syndrome (NMS)

Counsel patients about a potentially fatal adverse reaction - neuroleptic malignant syndrome (NMS) - that has been reported in association with administration of antipsychotic drugs. Advise patients to contact a healthcare provider or report to the emergency room if they experience signs or symptoms of NMS .

Tardive Dyskinesia

Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur . …

Warnings & precautions

Do not take this medicine if: Brexpiprazole tablets are contraindicated in patients with a known hypersensitivity to brexpiprazole or any of its components. Reactions have included rash, facial swelling, urticaria, and anaphylaxis.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.

Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Brexpiprazole tablets are not approved for the treatment of patients with dementia-related psychosis .

In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and over 4400 pediatric patients, the incidence of suicidal thoughts and behaviors in patients age 24 years and younger was greater in antidepressant-treated patients than in placebo-treated patients. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 2.

No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on suicide.

*Brexpiprazole tablets are not approved in pediatric patients with MDD. …

Brexpiprazole side effects

The following adverse reactions are discussed in more detail in other sections of the labeling:

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Suicidal Thoughts and Behaviors in Adolescents and Young Adults

Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis

Neuroleptic Malignant Syndrome (NMS)

Tardive Dyskinesia

Metabolic Changes

Pathological Gambling and Other Compulsive Behaviors

Leukopenia, Neutropenia, and Agranulocytosis

Orthostatic Hypotension and Syncope

Falls

Seizures

Body Temperature Dysregulation

Dysphagia

Potential for Cognitive and Motor Impairment

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Major Depressive Disorder

The safety of brexpiprazole tablets was evaluated in 1054 adult patients (18 to 65 years of age) diagnosed with MDD who participated in two 6-week placebo-controlled, fixed-dose clinical trials in patients with major depressive disorder in which brexpiprazole tablets was administered at doses of 1 mg to 3 mg daily as adjunctive treatment to continued antidepressant therapy; patients in the placebo group continued to receive antidepressant therapy . …

Drug interactions

* In the clinical trials examining the adjunctive use of brexpiprazole tablets in the treatment of MDD, dosage was not adjusted for strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). Thus, CYP considerations are already factored into general dosing recommendations, and brexpiprazole tablets may be administered without dosage adjustment in patients with MDD.

Strong CYP3A4 Inhibitors

Clinical Impact: | Concomitant use of brexpiprazole tablets with strong CYP3A4 inhibitors increased the exposure of brexpiprazole compared to the use of brexpiprazole tablets alone .

Intervention: | With concomitant use of brexpiprazole tablets with a strong CYP3A4 inhibitor, reduce the brexpiprazole tablets dosage .

Strong CYP2D6 Inhibitors*

Clinical Impact: | Concomitant use of brexpiprazole tablets with strong CYP2D6 inhibitors increased the exposure of brexpiprazole compared to the use of brexpiprazole tablets alone .

Intervention: | With concomitant use of brexpiprazole tablets with a strong CYP2D6 inhibitor, reduce the brexpiprazole tablets dosage . …

About this medicine

Brexpiprazole, an atypical antipsychotic, is available as brexpiprazole tablets. Brexpiprazole is 7-{4-[4-(1- Benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one. The molecular formula is C25H27N3O2S and its molecular weight is 433.57. The chemical structure is:

Brexpiprazole tablets are for oral administration and are available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths. Inactive ingredients include microcrystalline cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, propylene glycol, polyethylene glycol. Colorants includes titanium dioxide, iron oxide red (0.25 mg and 3 mg), FD&C Yellow #6 (0.5 mg), iron oxide yellow (1 mg, 2 mg and 3 mg), FD&C Blue #2 (2 mg).

How it works: The mechanism of action of brexpiprazole in the treatment of major depressive disorder or schizophrenia is unknown. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 993b584c-7fe6-4551-899f-39146c8508ac. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone